Logo image of DRNA

Dicerna Pharmaceuticals Inc (DRNA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DRNA - Common Stock

38.22
+0.22 (+0.58%)
Last: 12/27/2021, 8:42:47 PM
38.24
+0.02 (+0.05%)
After Hours: 12/27/2021, 8:42:47 PM
Fundamental Rating

2

DRNA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While DRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. DRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DRNA had negative earnings in the past year.
DRNA Yearly Net Income VS EBIT VS OCF VS FCFDRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 100M -100M

1.2 Ratios

Industry RankSector Rank
ROA -16.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRNA Yearly ROA, ROE, ROICDRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -50 -100

1.3 Margins

The Operating Margin and Gross Margin are not available for DRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -64.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRNA Yearly Profit, Operating, Gross MarginsDRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

DRNA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for DRNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRNA Yearly Shares OutstandingDRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M
DRNA Yearly Total Debt VS Total AssetsDRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 200M 400M 600M

2.2 Solvency

DRNA has an Altman-Z score of 1.63. This is a bad value and indicates that DRNA is not financially healthy and even has some risk of bankruptcy.
DRNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.63
ROIC/WACCN/A
WACCN/A
DRNA Yearly LT Debt VS Equity VS FCFDRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M 100M 150M 200M

2.3 Liquidity

DRNA has a Current Ratio of 2.46. This indicates that DRNA is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.46 indicates that DRNA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46
DRNA Yearly Current Assets VS Current LiabilitesDRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DRNA have decreased by -1.24% in the last year.
DRNA shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.85%.
The Revenue has been growing by 282.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y282.76%
Sales Q2Q%28.79%

3.2 Future

DRNA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
DRNA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.70% yearly.
EPS Next Y-13.03%
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%
EPS Next 5Y0.58%
Revenue Next Year-6.12%
Revenue Next 2Y2.93%
Revenue Next 3Y-3.27%
Revenue Next 5Y-2.7%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DRNA Yearly Revenue VS EstimatesDRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
DRNA Yearly EPS VS EstimatesDRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRNA Price Earnings VS Forward Price EarningsDRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -20.61
DRNA Per share dataDRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

DRNA's earnings are expected to decrease with -20.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%

More info and screens

0

5. Dividend

5.1 Amount

DRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Dicerna Pharmaceuticals Inc

NASDAQ:DRNA (12/27/2021, 8:42:47 PM)

After market: 38.24 +0.02 (+0.05%)

38.22

+0.22 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/amc
Inst Owners0.69%
Inst Owner Change0%
Ins Owners4.73%
Ins Owner Change0%
Market Cap2.97B
Revenue(TTM)192.85M
Net Income(TTM)-124.45M
Analysts71.43
Price Target37.16 (-2.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.41
P/FCF N/A
P/OCF N/A
P/B 27.6
P/tB N/A
EV/EBITDA -20.61
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.48
BVpS1.38
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -64.53%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z 1.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y-13.03%
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%
EPS Next 5Y0.58%
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y282.76%
Sales Q2Q%28.79%
Revenue Next Year-6.12%
Revenue Next 2Y2.93%
Revenue Next 3Y-3.27%
Revenue Next 5Y-2.7%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Dicerna Pharmaceuticals Inc / DRNA FAQ

What is the fundamental rating for DRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to DRNA.


Can you provide the valuation status for Dicerna Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 0 / 10 to Dicerna Pharmaceuticals Inc (DRNA). This can be considered as Overvalued.


How profitable is Dicerna Pharmaceuticals Inc (DRNA) stock?

Dicerna Pharmaceuticals Inc (DRNA) has a profitability rating of 4 / 10.


What is the financial health of Dicerna Pharmaceuticals Inc (DRNA) stock?

The financial health rating of Dicerna Pharmaceuticals Inc (DRNA) is 4 / 10.


How sustainable is the dividend of Dicerna Pharmaceuticals Inc (DRNA) stock?

The dividend rating of Dicerna Pharmaceuticals Inc (DRNA) is 0 / 10 and the dividend payout ratio is 0%.